Citation for published version (APA):
Agonist-induced sensitisation of the irritant receptor ion channel TRPA1

Running title: Agonist-induced sensitisation of TRPA1

Jannis E. Meents¹,², Michael J. M. Fischer¹,³, Peter A. McNaughton¹,⁴

¹Department of Pharmacology, University of Cambridge, CB2 1PD, United Kingdom
²Institute of Physiology, Uniklinik RWTH Aachen, 52074, Germany
³Institute of Physiology and Pathophysiology, University of Erlangen-Nuremberg, 91054, Germany
⁴Wolfson Centre for Age-Related Diseases, King’s College London, SE1 1UL, United Kingdom

Corresponding author:
Prof Peter A. McNaughton
Wolfson Centre for Age-Related Diseases, King’s College London
Guys Campus, Wolfson Wing, Hodgkin Building
London, SE1 1UL
Email: peter.mcnaughton@kcl.co.uk

Key words: TRPA1, sensitisation, inflammation
Key Points Summary

- The Transient Receptor Potential Ankyrin 1 (TRPA1) ion channel is expressed in nociceptive neurons and its activation causes ongoing pain and inflammation. TRPA1 is thought to play an important role in inflammation in the airways.

- TRPA1 is sensitised by repeated stimulation with chemical agonists in a calcium-free environment. This sensitisation is very long-lasting following agonist removal.

- We show that agonist-induced sensitisation is independent of the agonist’s binding site and is also independent of ion channel trafficking or of other typical signalling pathways.

- We find that sensitisation is intrinsic to the TRPA1 protein and is accompanied by a slowly developing shift in the voltage dependence of TRPA1 towards more negative membrane potentials.

- Agonist-induced sensitisation may provide an explanation for sensitisation following long-term exposure to harmful irritants and pollutants, particularly in the airways.
Abstract

The TRPA1 ion channel is expressed in nociceptive (pain-sensitive) neurons and responds to a wide variety of chemical irritants, such as acrolein in smoke or isothiocyanates in mustard. Here we show that in the absence of extracellular calcium the current passing through TRPA1 gradually increases (sensitises) during prolonged application of agonists. Activation by an agonist is essential, because activation of TRPA1 by membrane depolarisation did not cause sensitisation. Sensitisation is independent of the site of action of the agonist, because covalent and non-covalent agonists were equally effective, and is long-lasting following agonist removal. Mutating N-terminal cysteines, the target of covalent agonists, did not affect sensitisation by the non-covalent agonist carvacrol, which activates by binding to a different site. Sensitisation is unaffected by agents blocking ion channel trafficking or by block of signalling pathways involving ATP, protein kinase A or the formation of lipid rafts, and does not require ion flux through the channel. Examination of the voltage dependence of TRPA1 activation shows that sensitisation is accompanied by a slowly developing shift in the voltage dependence of TRPA1 towards more negative membrane potentials, and is therefore intrinsic to the TRPA1 channel. Sensitisation may play a role in exacerbating the pain caused by prolonged activation of TRPA1.

Abbreviations

TRPA1, Transient Receptor Potential Ankyrin 1; AITC, Allyl isothiocyanate; DRG, dorsal root ganglion; HEK293t, Human embryonic kidney 293t cell line; MβCD, Methyl-β-cyclodextrin; PKA, Protein kinase A; WTA, Wheat germ agglutinin; WT, wildtype
Introduction

The Transient Receptor Potential Ankyrin 1 (TRPA1) channel is unique in its ability to respond to a wide range of irritant agonists, many found in the everyday environment, hence the term “irritant receptor”. The channel is expressed in neurons of somatosensory ganglia (Story et al., 2003; Jordt et al., 2004; Nagata et al., 2005; Anand et al., 2008) and its agonists trigger pain and inflammation. Electrophilic agonists, such as allyl-isothiocyanate (AITC, mustard oil), cinnamaldehyde, formaldehyde and acrolein activate TRPA1 by forming covalent bonds with three intracellular N-terminal cysteine residues (Story et al., 2003; Bandell et al., 2004; Bautista et al., 2006; Hinman et al., 2006; McNamara et al., 2007; Macpherson et al., 2007). Non-electrophilic agonists, such as menthol, carvacrol (contained in oregano) and nicotine activate TRPA1 without causing modification of cysteines (Karashima et al., 2007; Lee et al., 2008; Talavera et al., 2009). TRPA1 is also activated by a range of endogenous ligands (Andersson et al., 2008; Eberhardt et al., 2012), protons (de la Roche et al., 2013), and possibly by noxious cold temperatures, although this remains controversial (Story et al., 2003; Jordt et al., 2004; Bautista et al., 2006; Zurborg et al., 2007; Karashima et al., 2009; Gentry et al., 2010). Intracellular and extracellular calcium activate TRPA1 and potentiate its response to several agonists; the activation is followed by long lasting inactivation of the channel (Jordt et al., 2004; Zurborg et al., 2007; Doerner et al., 2007a; Wang et al., 2008b).

Behavioural studies in rodents as well as genome wide association studies in humans demonstrate a role for TRPA1 in nociception, making the channel a promising target for the development of novel analgesics (Obata et al., 2005; Bautista et al., 2006; Kwan et al., 2006; Caceres et al., 2009; Kremeyer et al., 2010; Bell et al., 2014). As many of its agonists can potentially be inhaled, TRPA1 has become an important target for the treatment of inflammatory airway diseases.
Inflammation releases a range of inflammatory mediators which cause a lowering of the
activation threshold of peripheral nociceptive nerve fibers. TRPA1 is sensitised by
bradykinin or by activators of proteinase-activated receptor 2 (PAR2) via activation of
intracellular pathways involving protein kinase A (PKA) and phospholipase C (Dai et
al., 2007; Wang et al., 2008a; Schmidt et al., 2009). TRPA1 can also be sensitised by
prolonged application of agonists in calcium-free conditions (Raisinghani et al., 2011).
Such agonist-induced sensitisation could be important for the body’s response during
prolonged exposure to irritants and allergens. Elucidating the mechanism behind
agonist-induced sensitisation is important in understanding both the function of TRPA1
and its role in pathologies such as lung inflammation.

Here, we investigate agonist-induced sensitisation of human TRPA1 and we show that
this process is independent of the principal cell signalling pathways and also does not
involve enhanced channel trafficking to the cell membrane. We find that agonist-
induced sensitisation is accompanied by a slow shift of the voltage dependence of
channel activation towards more negative membrane potentials, leading to a slowly
developing and long-lasting gain in channel activation. The shift is rapidly reversed on
removal of agonist but rapidly reappears on re-presentation of the agonist. We suggest
that activation by an agonist causes sensitisation through a long-lasting and slowly-
reversible change in the structure of TRPA1.

Materials and Methods

Ethical Approval

Studies involving animals were approved by the Home Office (UK) and by the Animal
Welfare and Ethical Review Body, University of Cambridge.
Cell culture and transfection

Cell culture was performed as previously described (Fischer et al., 2013) with the following changes. Dorsal root ganglia (DRGs) were collected from C57BL/6 mice of either sex aged 6–16 weeks, sacrificed by cervical dislocation. Harvested ganglia were transferred into calcium- and magnesium-free Hank’s Balanced Salt Solution and treated with 2 mg/ml papain (Sigma-Aldrich, UK), followed by 2.5 mg/ml collagenase type IV (Invitrogen) for 30 min at 30°C. HEK293t cells were transfected using Metafectene (Biontex Laboratories GmbH, Martinsried/Planegg, Germany) according to the manufacturer’s instructions. Electrophysiological recordings were performed on the day following the transfection. All experiments were performed at room temperature.

Plasmids, cloning and mutagenesis

Human TRPA1-V5 was obtained from Dr Xuming Zhang (University of Aberdeen, Scotland). Human TRPA1 cDNA (hTRPA1) was subcloned into a pcDNA5/FRT-mTRPA1-IRE-ES-YFP vector, using HindIII and XbaI. The vector was a kind gift from Dr Ardem Patapoutian (Scripps Research Institute, La Jolla, CA). The hTRPA1 cDNA containing three cysteine-to-serine mutations (C621S, C641S, C665S) was obtained from Dr Carla Nau (University Medical Center Schleswig-Holstein, Lübeck, Germany) and was cloned into the same pcDNA5/FRT-IRE-ES-YFP vector. All constructs were confirmed by sequencing.

Calcium imaging

Ratiometric calcium imaging was performed using the calcium-sensitive dye fura-2. Cells were loaded with fura-2 AM (5 μM) in the presence of 0.02% pluronic F-127 (both Invitrogen) for 30 min at 37°C in serum- and antibiotic-free DMEM. Medium was changed to HEPES-buffered extracellular solution (in mM: 140 NaCl, 4 KCl, 1.8 CaCl₂, 1 MgCl₂, 10 HEPES, and 5 glucose, adjusted to pH 7.4) and neurons were left to
equilibrate at room temperature in the dark for 5 min and then mounted on a Nikon
Eclipse Ti-E inverted microscope with a 10× Plan Fluor objective. Cells were
continuously superfused with extracellular solution or test solutions through a common
outlet. Cells were illuminated with a monochromator alternating between 340 ± 10 and
380 ± 10 nm (OptoScan; Cairn Research Ltd, Faversham, UK), controlled by WinFluor
3.2 software (Dr John Dempster, University of Strathclyde, Glasgow, UK). Ratiometric
calcium imaging as described above was also used to identify DRG neurons
expressing TRPA1 for patch clamp recordings from their responsiveness to AITC.
Neurons were exposed to AITC (50 µM) for 40 s and responders identified. A selected
neuron was then patched for whole-cell voltage clamp recordings. Immediately after
establishing the whole-cell configuration perfusion was switched to calcium-free
extracellular solution for 2 min before beginning the voltage clamp recording. Note that
at least 5 min passed between the end of the AITC application and the start of the
voltage clamp recording.

Patch clamp electrophysiology

Whole-cell voltage clamp was performed on transfected HEK293t cells or on DRG
neurons selected by calcium imaging (see above). Membrane currents were acquired
with an Axopatch 200B amplifier (Molecular Devices, Wokingham, UK), low-pass
filtered at 2 kHz and sampled at 10 kHz. The pClamp 9 or 10 software (Molecular
Devices, Wokingham, UK) was used for acquisition and offline analysis. Series
resistance was compensated up to 75%. Glass electrodes (GB150F-8P; Science
Products GmbH, Hofheim, Germany) were fabricated (P-97; Sutter Instruments,
Novato, USA) and heat polished on a microforge (MF-830; Narishige International Ltd,
Tokyo, Japan) to a final resistance of 2–5 MΩ. Cells were continuously superfused with
extracellular solution or test solutions through a common outlet. Solution changes were
controlled by an automated system using pinch-valves designed by Dr. V. Vellani (CV
Scientific, Inc). Solution changes at the cell position were complete (10% – 90% concentration change) within 100 ms, which was significantly more rapid than the time course of TRPA1 current activation in response to agonist (see below). All recordings were performed in calcium-free HEPES-buffered extracellular solution (see above). In experiments using ATP-free intracellular solution the extracellular solution contained no glucose. In experiments designed to evoke maximal TRPA1 currents using 5 mM carvacrol, external sodium was reduced to 10 mM to reduce voltage-clamp artefacts caused by large current flows. NaCl was substituted by choline-chloride (130 mM), and titrated with CsOH. The internal solution contained the following (in mM): 140 KCl, 1.6 MgCl$_2$, 2.5 MgATP, 0.5 NaGTP, 2 EGTA, and 10 HEPES, adjusted to pH 7.3. In ATP-free experiments, MgATP and NaGTP were substituted with MgCl$_2$ and NaCl$_2$, respectively. All experiments were performed at room temperature and at a holding potential of −60 mV.

To investigate voltage dependence, a 500 ms voltage ramp protocol from −100 mV to +100 mV was applied every 5 s. Voltage dependence was also tested at given time points using 80 ms voltage pulses ranging from −140 mV to +220 mV in 30 mV increments from a holding potential of −60 mV, followed by a step to +60 mV for 80 ms for tail current analysis, and a final step back to −60 mV for 160 ms (see Figure 6 B). TRPA1 currents were corrected for leak conductance obtained from a hyperpolarising pulse to −140 mV in the absence of agonist. Half-maximal voltage gating ($V_{1/2}$) was obtained from tail currents, normalised to the maximum tail currents measured on each individual cell during the second application of carvacrol ($I_t/I_{t,max}$). Normalised tail current-voltage relationships were then fitted to a Boltzmann equation:

$$\frac{I_t}{I_{t,max}} = I_{t,min} + \left(\frac{I_{t,max} - I_{t,min}}{(V_{1/2} - V)}\right) \frac{1}{1 + e^{-\frac{V - V_{1/2}}{\text{slope}}}}.$$
where \( I_{t,\text{min}} \) and \( I_{t,\text{max}} \) are the minimum and maximum tail currents, respectively, \( V \) is the membrane voltage and slope is an inverse measure of the steepness at inflection. Tail current analysis was restricted to the voltage domain below +100 mV in order to avoid channel inactivation at strong positive potentials (see Results section, Figure 6).

**Modelling**

As an *in silico* model, four states and the transitions between these were modelled. To calculate the time course of channel opening or closing, the activating or deactivating component of the current traces were fitted by a mono-exponential function:

\[
y(x) = A e^{-x/\tau} + C,
\]

where \( y(x) \) and \( C \) represent the current amplitude at time \( x \) and at steady-state, respectively, \( A \) is the current amplitude, and \( \tau \) is the time constant. To determine the time constant of the slow agonist-induced effect, the \( V_{1/2} \) shifts at 0 s, 10 s, 60 s, 120 s as well as 180 s and 240 s (cumulative) were considered and fitted by a double-exponential function (Figure 7 C):

\[
y(x) = y_0 + A_1 e^{-x/\tau_1} + A_2 e^{-x/\tau_2},
\]

where in addition to the above-mentioned parameters, \( y_0 \) represents the current amplitude at time 0. The first exponential time constant \( \tau_1 \) was pre-set to 3.1 s (see Results section). To reject outliers, log-transformed time constants outside of mean \( \pm 2\sigma \) were ignored.

In our model, \( \tau_1 \) is the time constant of the net transition rate from the closed (C) to the open (O) channel state on application of agonist, \( \tau_2 \) is the time constant of the reverse process, occurring on removal of the agonist. \( \tau_3 \) is the time constant of the transition from state 0 (unsensitised) to state 1 (sensitised) in the presence of the agonist, applicable to both closed and open channels. Based on these transition time constants,
1 the stochastically expected net transition was calculated for finite time periods of 0.1 s.
2 The fraction of open channels was calculated for every state separately based on the
3 Boltzmann equation above \((I/I_{t,max})\) and cumulated.

4 **Immunocytochemistry**

5 To examine trafficking of TRPA1 to the cell membrane, HEK 293t cells, transiently
6 transfected with hTRPA1-V5, were treated with 100 µM carvacrol or with vehicle
7 (control) in calcium-free extracellular solution for 5 min at room temperature prior to
8 fixation. Immunocytochemistry was then performed as previously described (Btesh et al.,
9 2013). The following antibodies were used: mouse anti-V5 (1:1000; Invitrogen, Life
10 Technologies Ltd, Paisley, UK) primary for 3 h, followed by Alexa Fluor 488 anti-mouse
11 secondary (1:1000; Life Technologies, Paisley, UK) for 1 h.

12 **Chemicals**

13 Carvacrol, AITC, MβCD and Brefeldin A were all purchased from Sigma-Aldrich
14 (Gillingham, UK). H89 was purchased from Cayman Chemical (Ann Arbor, USA).
15 HC030031 was a kind gift from Dr Sarah Skerratt, Neusentis, Pfizer (Granta Park,
16 Cambridge, UK). AITC, H89 and HC030031 were dissolved in DMSO. The final
17 concentration of DMSO did not exceed 0.1 %. Carvacrol was diluted directly in calcium-
18 free HEPES-buffered extracellular solution and Brefeldin A was dissolved in ethanol.
19 MβCD was dissolved in cell culture medium and cells incubated prior to the start of the
20 experiment.

21 **Data analysis**

22 Repetitive application of TRPA1 agonists such as carvacrol caused a steady increase
23 in response amplitude (see for example Figures 1 & 2). In order to limit the time taken
24 for recordings, and to reduce variability which may be caused by cell deterioration in
very long experiments, we quantified fractional agonist-induced sensitisation under
different conditions as the peak current induced by the sixth agonist application divided
by the peak current induced by the first application.

Two groups of data containing < 10 samples were compared using the nonparametric
U test. Two groups of data containing ≥ 10 samples were compared using the paired or
unpaired t-test as appropriate. Multiple groups were compared by one-way or repeated
measures ANOVA followed by either Dunnett’s multiple comparison or Bonferroni post
hoc test as appropriate. Recovery ratios in Figure 5 D were statistically compared to
the value of 1 using a one-sample t-test. Statistical analysis was performed using
Statistica 8 (StatSoft, Bedford, UK) or Prism 6 (GraphPad Software, Inc., La Jolla,
USA). Data are presented as mean ± SEM; p < 0.05 was considered significant.
Significance levels are as follows: n.s., not significant; *p < 0.05; **p < 0.01; ***p <
0.001.

Results

Repeated agonist-induced activation sensitises TRPA1

Responses of TRPA1 in DRG neurons to a submaximal dose of AITC have been
shown to increase with each application under calcium-free conditions (Raisinghani et
al., 2011). Here, we confirmed that repeated application of the electrophilic agonist
AITC (50 µM) induces increasing inward currents in adult mouse DRG neurons
expressing TRPA1 (Figure 1 A, C). The non-electrophilic TRPA1 agonist carvacrol (100
µM), which activates TRPA1 at a different agonist binding site (Lee et al., 2008) also
induced increasing inward currents (Figure 1 B, C). Both agonists also induced a
similar sensitisation in HEK293t cells expressing hTRPA1 (Figure 1 D–F).
TRPA1 can also be activated by strong depolarising voltage steps in the absence of agonist (Figure 1 G; see also Figure 6). The time-dependent activation during the pulse, and the current deactivated on return to the holding potential, are both TRPA1-dependent as much smaller and time-independent currents are observed in untransfected cells (Figure 1 H). However, in contrast to the increasing current activated by repeated agonist application, we found that TRPA1 currents elicited by depolarisation were stable and did not show any sign of sensitisation, either during a train of activating pulses or when the train was repeated after 5 min (Figure 1 I). Sensitisation was also not observed with longer voltage pulses, of the same duration as the exposures to carvacrol in Figure 1 E (Figure 1 J–K).

Sensitisation of TRPA1 is independent of N-terminal cysteine modification or cell signalling pathways

Activation of TRPA1 by electrophilic agonists such as AITC depends on the covalent modification of three N-terminal cysteine residues, C621, C641 and C665 (Hinman et al., 2006; Macpherson et al., 2007). We mutated all three cysteine residues to serine (hTRPA1-C621S-C641S-C665S, 3C mutant), and used the non-electrophilic agonist carvacrol to activate TRPA1. Repeated application of carvacrol still potently sensitised TRPA1 (Figure 2 A, F), showing that the three cysteine residues are not required for agonist-induced sensitisation.

Next, we tested if cell signalling pathways utilising intracellular ATP were responsible for sensitising TRPA1, a mechanism that is well known for the TRPV1 ion channel (Cesare & McNaughton, 1996; Tominaga et al., 2001; Vellani et al., 2001). However, removing all ATP and GTP from the intracellular solution and all glucose from the extracellular solution to prevent metabolic production of ATP did not reduce carvacrol-induced sensitisation, and surprisingly sensitisation was significantly more potent compared to control experiments (Figure 2 B, F).
TRPA1 has been reported to be sensitised by inflammatory mediators via activation of intracellular protein kinase A (PKA), although this has been disputed in a later study (Wang et al., 2008a; Raisinghani et al., 2011). However, applying the PKA inhibitor H89 (10 µM) did not reduce agonist-induced sensitisation of TRPA1 (Figure 2 C, F). This concentration of H89 was chosen as it has previously shown to be effective in blocking bradykinin or forskolin-induced activation of PKA (Wang et al., 2008a; and JEM unpublished data).

Migration of ion channels into lipid rafts has been reported to potentiate their activation (Liu et al., 2006; Szőke et al., 2010). Lipid rafts can be disrupted by depletion of cholesterol from the cell membrane by methyl-β-cyclodextrin (MβCD). However, incubation of hTRPA1-expressing HEK293t cells in MβCD before the recording did not influence the sensitisation induced by repeated application of carvacrol (Figure 2 D, F). We used MβCD at a similar time of application and concentration that has been shown to diminish capsaicin-induced responses in TRPV1-expressing cells (Szőke et al., 2010).

Finally, we observed that an initial sustained carvacrol application causes slow sensitisation, as seen in a slow increase of inward current (Figure 2 E). Once the channel has fully entered the sensitised state, little further sensitisation is seen during repetitive application of agonist (Figure 2 E, F).

**Trafficking of TRPA1 to the membrane is not involved in carvacrol-induced sensitisation**

It has previously been reported that TRPA1 ion channels can be trafficked to and inserted into the cell membrane in response to activation of the channel by AITC and it was argued that this mechanism contributes to increased sensitivity of neurons to TRPA1 agonists (Schmidt et al., 2009). We therefore investigated whether enhanced
trafficking might be responsible for agonist-induced sensitisation of TRPA1. HEK293t cells transfected with hTRPA1-V5 were exposed to carvacrol (100 µM) for 5 min in a calcium-free solution, similar to the carvacrol exposure in Figure 2 E. TRPA1 was detected using a V5 antibody, and wheat germ agglutinin (WGA) was used to define the location of the plasma membrane (Btesh et al., 2013). However, no difference was observed in the presence of TRPA1 at the cell membrane after carvacrol treatment when compared to control cells treated with vehicle (Figure 3 A–C).

To extend these findings we repeated the electrophysiological recordings described above on hTRPA1-expressing HEK293t cells that had been incubated with the protein transport inhibitor Brefeldin A (5 µg/ml). Brefeldin A has been successfully used to block trafficking of other ion channels, such as P2X (Fabbretti et al., 2006; Lalo et al., 2010) and TRPV1 (Johansen et al., 2006). However, blocking trafficking with brefeldin A had no effect on the sensitisation induced by repeated application of carvacrol (Figure 3 D, E).

We next measured surface membrane TRPA1 expression directly by maximally activating TRPA1 with a saturating dose of 5 mM carvacrol. The large membrane currents observed with maximal activation were reduced by removing all but 10 mM extracellular Na⁺ in order to avoid patch clamp artefacts. Instead of the increasing inward currents that would be expected if exposure to agonist had induced trafficking of TRPA1 to the membrane, we instead observed tachyphylaxis of the induced responses (Figure 3 F, G). These results are in accordance with those obtained by another group (Raisinghani et al., 2011) and argue against increased channel insertion into the cell membrane.
Sensitisation is independent of agonist site-of-action and of ion flux

Electrophilic agonists, such as AITC, activate the channel via intracellular N-terminal cysteine modification (Hinman et al., 2006; Macpherson et al., 2007), while non-electrophilic agonists such as menthol activate by binding to a site within transmembrane domain 5 (Xiao et al., 2008a). Carvacrol also acts at the same site as menthol, because mutating two amino acids, S873 and T874, within transmembrane domain 5 of hTRPA1 to valine and leucine, respectively, completely abolished sensitivity to carvacrol but not to AITC (Figure 4 C–E). We studied cross-sensitisation between AITC and carvacrol to investigate whether the sensitisation induced by a specific agonist is limited to activation at its own binding site. Sensitisation was induced with either AITC or carvacrol, followed by a test of sensitisation by applying a pulse of carvacrol. Channel activation by either agonist caused equivalent sensitisation (Figure 4 A), and in cells exposed to AITC, the following carvacrol response was significantly sensitised compared to control cells not exposed to AITC (Figure 4 B). Sensitisation is therefore independent of the agonist’s site of action.

The S873V/T874L mutant allowed us to examine the possibility that carvacrol might cause sensitisation by binding to a site other than that at which it activates the ion channel. Application of carvacrol to the S873V/T874L mutant failed to activate the channel (Figure 4 C–E) and also failed to cause any sensitisation, as probed by a subsequent pulse of AITC (Figure 4 F). Thus both activation and sensitisation are mediated by binding of carvacrol to an activation domain containing the S873V/T874L site.

We used the TRPA1 antagonist HC030031 to test if channel block could abolish carvacrol-induced sensitisation. Channel block during a series of applications of carvacrol did not affect sensitisation because responses after channel block were comparable in amplitude to recordings where no antagonist had been applied (Figure 5.
A) and were significantly increased compared to responses before channel block (Figure 5 B). To investigate the time course of recovery from carvacrol-induced sensitisation, we applied carvacrol with variable gaps between each application (Figure 5 C) and found no evidence for recovery over 240 s (Figure 5 D).

Prolonged activation of TRPA1 by an agonist as shown in Figure 5 C (see inset) showed the existence of two distinct processes during sustained channel activation. The initial current increase reached a plateau within a few seconds, which was followed by a delayed secondary current increase with a similar time course as the onset of sensitisation.

Taken together, the results described in this section show that sensitisation is driven when TRPA1 is activated by agonists but not by voltage. Sensitisation has a slow onset, reverses very slowly in the absence of agonist, and is independent of cell signalling pathways.

**Sensitisation is accompanied by a change in dependence of TRPA1 on membrane voltage**

To investigate whether sensitisation induced by carvacrol may be accompanied by changes in the intrinsic gating properties of TRPA1 we compared the voltage-dependent activation of TRPA1 in unsensitised and sensitised states. Under calcium-free conditions we applied carvacrol (100 µM) while testing for current activation using a rapid ramp protocol (Figure 6 A). At the indicated time points before and during carvacrol, we used a protocol of repeated voltage pulses to examine the voltage dependence of activation (Figure 6 B). Steady-state current at the end of each test pulse was used to obtain the $I-V$ relationship (Figure 6 C, D) and the tail current at +60 mV following each pulse was used to calculate the voltage dependence of channel activation (Figure 6 E).
Before application of carvacrol, voltage-dependent activation was observed only at strongly positive potentials (Figure 6 B, C; time point 1). Application of carvacrol (100 µM) induced an increase in steady-state currents at all voltages (time point 2) which gradually increased (time points 3, 4). Moreover, we observed channel inactivation at strongly depolarised voltages following prolonged application of carvacrol (time point 4). After washout of carvacrol, activation only by strongly positive membrane voltages was restored (Figure 6 D; time point 5). Surprisingly, when we measured voltage dependence again during a second carvacrol application, there was a marked negative shift in the I-V relationship between each time point and its corresponding point during the first application (compare Figure 6 C and D). Steady-state current at +70 mV at the end of the second carvacrol application (time point 8) had increased by 33 % compared to the end of the first application (time point 4). Note that there is not an exact correspondence between current measured with the rapid ramp protocol in Figure 6 A, which does not allow current to reach a steady-state, and the steady-state current measured with the step protocol in Figure 6 B.

We next used tail currents at +60 mV as a measure of the voltage dependence of channel activation (Figure 6 E). Corresponding to our observations above, TRPA1 was activated only at strongly depolarised membrane potentials in the absence of agonist (time point 1), which is in agreement with previous reports (Meseguer et al., 2008; Fajardo et al., 2008) although others have reported stronger activation at potentials above +100 mV (Karashima et al., 2007; Zurborg et al., 2007). With prolonged agonist application (see time points 4 and 8) tail currents were reduced following strong depolarisations, with currents reaching a maximum at +70 mV and then decreasing steadily (Figure 6 E). Voltage-dependent TRPA1 channel inactivation at strongly positive membrane potentials has been noted in previous publications (Karashima et al., 2007, 2008; Macpherson et al., 2007; Andersson et al., 2008; Fajardo et al., 2008;
Talavera et al., 2009) and the basis for this inactivation is unknown. In analysing tail currents we therefore restricted analysis to the voltage domain below +100 mV. Voltage-dependent activation of TRPA1 was quantified from tail currents normalised to the maximum tail current measured for each individual cell during either of the two responses. These tail current-voltage relationships were fitted by a Boltzmann function to calculate the voltage at which current was half-activated, $V_{1/2}$ (Figure 6E). In the absence of agonist, we measured a $V_{1/2}$ of $+170 \pm 13$ mV, which is similar albeit slightly higher than what has been previously reported for TRPA1 (Karashima et al., 2007; Zurborg et al., 2007; Kremeyer et al., 2010). During application of carvacrol, we found an initial rapid negative shift of the activation $V_{1/2}$; after 10 s exposure $V_{1/2}$ was $+94 \pm 16$ mV ($p = 0.05$ when compared to time point 1; $n = 11$). A slow negative shift followed; after 60 s exposure, $V_{1/2}$ had shifted to $+34 \pm 20$ mV (not shown; $p < 0.001$ compared to time point 1; $n = 11$) and after 120 s exposure, $V_{1/2}$ had shifted even further to $-36 \pm 24$ mV ($p < 0.001$ compared to time point 1; $n = 11$; all Repeated Measures ANOVA with Bonferroni post hoc analysis) (Figure 6E). Corresponding to observations from steady-state $I$-$V$ relationships, tail current-voltage relationships returned to baseline values between carvacrol applications (time point 5; $+179 \pm 14$ mV; $p = 0.99$ compared to time point 1), indicating that the shift of the activation curve was not due to factors such as progressive dialysis of the intracellular solution. The activation curves during the second carvacrol application, which had been shown in other experiments to cause significant sensitisation, were all shifted towards more negative potentials when compared to the corresponding time points in the first carvacrol application, indicating that part of the negative shift had been conserved between applications. We measured an activation $V_{1/2}$ of $+22 \pm 12$ mV ($p = 0.08$), $-93 \pm 25$ mV ($p < 0.001$) and $-132 \pm 18$ mV ($p = 0.003$) after 10 s, 60 s and 120 s of the second application, respectively (all compared to corresponding time points in the first
carvacrol application; \( n = 11 \); Repeated Measures ANOVA with Bonferroni post hoc analysis).

We next developed a model to explain the time course of sensitisation of TRPA1 activation during repetitive applications of carvacrol at a single agonist concentration and at a fixed membrane potential in experiments such as that shown in Figure 1 E. First, the transition from the closed to the open channel state was compared between the first and the 20\textsuperscript{th} carvacrol application (100 \( \mu \text{M} \), 15 s, holding potential \(-60 \text{ mV} \)), i.e. before and after agonist-induced sensitisation. The time constant of channel opening determined by a mono-exponential fit to the current traces was not significantly different between these applications (\( p = 0.43 \); paired t-test). Therefore the transition to the open state was modelled with a single constant \( \tau_1 = 3.1 \pm 1.1 \text{ s} \) in both the basal and the sensitised state. Similarly, the time constant of channel closing after agonist removal was fitted after the first and the 20\textsuperscript{th} application (\( p = 0.16 \); paired t-test) and the closing time constant was determined as \( \tau_2 = 1.5 \pm 0.5 \text{ s} \).

Based on these findings, we propose a model with two open and two closed conformations, either in the unsensitised (\( C_0-O_0 \)) or the sensitised channel state (\( C_1-O_1 \)) (Figure 7 A). Because time constants for agonist-dependent channel opening or closing are not different in the unsensitised or sensitised state (see above), we suggest that the rapid gating of TRPA1 by agonist and voltage (applicable for both \( C_0-O_0 \) and \( C_1-O_1 \)) is independent of the additional slow agonist-induced effect, which can be seen in the slow shift of voltage dependence (Figure 6 E) and which is described by a transition to an additional sensitised channel closed-open state (\( C_1-O_1 \)). We therefore suggest that sensitisation consists of a slow and progressive accumulation of channels in the sensitised state (\( C_1-O_1 \)). Since this slow effect is agonist-dependent, we modelled this with one time constant (\( \tau_3 \)) for both transitions \( C_0-C_1 \) and \( O_0-O_1 \). To determine the time constants of this process, the change in \( V_{1/2} \) at 0 s, 10 s, 60 s, 120 s
as well as 180 s and 240 s (cumulative) after exposure to carvacrol was fitted by a
double-exponential with the fast time constant being equal to the time constant for
transition $\tau_1 = 3.1$ s (see above) from the closed to the open state (Figure 7 C). The
slow time constant $\tau_3$ was taken to represent the transition from state 0 to state 1 and
was determined as $\tau_3 = 130 \pm 27$ s. In addition, this double-exponential fit resulted in a
$V_{1/2}$ shift from a baseline of $+174 \pm 11$ mV to $+99 \pm 13$ mV (75 mV shift) with time
constant $\tau_1$ and an additional $V_{1/2}$ shift to $-175 \pm 24$ mV with time constant $\tau_3$ (274 mV
shift) (see Figure 7 C).

With these parameters, a repetitive carvacrol application was modelled, considering the
four possible channel states, the described transitions, and the $V_{1/2}$-dependent open
probability of the four channel states at $-60$ mV using the described Boltzmann
equation (Figure 7 B). The time to reach a rapid equilibrium of the open probability is
an order of magnitude shorter than the slow $V_{1/2}$-shift and was therefore ignored in the
model. The modelled result shows a good agreement with the experimental
observations (see e.g. Figure 1 E), and can therefore explain the slow current increase.
At the end of the first application in the model 14% of all channels are open, while a
4.7-fold increase is predicted at the end of the 12$^{th}$ application (black trace). Figure 7 B
overlays the percentage of channels in state 1 (red trace) to demonstrate how the
observed current increase can be predicted by a slow transition to this state.

Because of the different values of $V_{1/2}$ in state O$_0$ and O$_1$, the model predicts that when
both states are occupied there will be a mixture of values of $V_{1/2}$ and therefore a
detectable decrease in the slope of conductance-voltage relationships. A minimum
slope is to be expected when 50% of channels are in each state (Figure 7 D). Indeed
this decrease was observed in our experiments (see Figure 6 E), the slope of the
current-voltage relationship at 120 s (time point 4) was significantly lower compared to
time points 2 and 8 ($p < 0.001$ and $p = 0.002$, respectively; Repeated Measures ANOVA with Bonferroni post hoc analysis; $n = 11$).

**Discussion**

We have shown that repeated activation of the irritant receptor TRPA1 by agonists, but not by membrane voltage, leads to a pronounced sensitisation of TRPA1 under calcium-free conditions. This agonist-induced sensitisation could be observed both in HEK293t cells expressing hTRPA1 and in adult mouse DRG neurons. Sensitisation is not limited to a specific class of agonist, as it is seen both with AITC and with carvacrol, which activate TRPA1 at different binding sites and by different mechanisms. In addition, the presence of intracellular ATP and the formation of lipid rafts, which are known to modulate TRPV1 (Tominaga *et al.*, 2001; Liu *et al.*, 2006; Szőke *et al.*, 2010), as well as activation of PKA, which has been shown to enhance activation of TRPA1 (Wang *et al.*, 2008a), are not involved in agonist-induced sensitisation of TRPA1. A further possibility is that exposure to agonists may increase trafficking and insertion of TRPA1 channels into the cell membrane, as has been proposed for sensitisation by AITC (Schmidt *et al.*, 2009). In the present study, however, we were not able to find any support for enhanced trafficking as an explanation for the sensitisation induced by agonists of TRPA1. It should be noted that AITC-induced trafficking of TRPA1, reported by Schmidt *et al.* (2009), was calcium-dependent and did not occur in a calcium-free environment, while the sensitisation reported in the present study was observed in the absence of extracellular calcium and is therefore likely to be a different phenomenon. Blocking intracellular protein transport with Brefeldin A, which blocks trafficking of P2X and TRP channels (Johansen *et al.*, 2006; Fabbretti *et al.*, 2006; Lalo *et al.*, 2010; Ma *et al.*, 2010), did not reduce sensitisation caused by carvacrol. Furthermore, we did not see an enhancement in maximal current activated by a saturating dose of agonist, as
would be expected if sensitisation was due to an increase in surface expression of TRPA1, and in fact observed tachyphylaxis of maximal responses.

Sensitisation is independent of the agonist’s site of action, because channel activation by AITC sensitised responses to carvacrol, even though the two agonists activate TRPA1 at distinct sites. Furthermore, sensitisation is independent of ion flux as it occurs during channel block by HC030031. Current traces during prolonged activation showed a pattern of two distinct phases, with a secondary increase in inward current that has a surprisingly slow time constant that exceeds by far the time constant of channel activation and even of pore dilation (Chen et al., 2009; Meseguer et al., 2014).

In the absence of evidence for other possible mechanisms, we hypothesised that the agonist-induced sensitisation of TRPA1 may depend on changes in the intrinsic gating properties of the channel. A similar pattern was found in the TRPV3 ion channel, which is also sensitised by repeated activation by heat and by agonists (Chung et al., 2005; Xu et al., 2006; Liu et al., 2011). Voltage-dependent gating of TRPA1 depends on a number of factors including the presence or absence of external calcium, the cell type and whether human or rodent TRPA1 is studied. Most studies used mouse TRPA1, expressed in Chinese hamster ovary cells (Karashima et al., 2007, 2009; Macpherson et al., 2007; Meseguer et al., 2008; Andersson et al., 2008; Fajardo et al., 2008; Talavera et al., 2009), before major species differences were discovered (Xiao et al., 2008a). In the present study we used the human isoform, transiently transfected into HEK293t cells.

**Synergy between activation of TRPA1 by agonists and by membrane voltage**

TRPA1 was found to be activated by strong depolarisation even in the absence of agonist, and carvacrol caused a shift of the voltage dependence of channel gating to more negative membrane potentials, as has been reported for other TRPA1 agonists...
and for cold temperatures (Karashima et al., 2007, 2009; Zurborg et al., 2007; Meseguer et al., 2008; Fajardo et al., 2008; Talavera et al., 2009). Here, we measured a $V_{1/2}$ of +170 mV under agonist-free conditions. The voltage-sensitivity of TRPA1 activation was very weak, with a mean value for the slope factor of 54.9 mV (Figure 6 E). This corresponds to a gating charge movement of $z = 0.46$ for all four subunits across the full electric field, or $z = 0.12$ per subunit. The value of $z$ obtained here is similar to that previously reported (0.375, Karashima et al., 2009) and corresponds to movement of a single charge per subunit across only a small fraction (12%) of the membrane field.

The $V_{1/2}$ was rapidly shifted in the negative direction by agonist, to +94 mV following 10s application of carvacrol, and then became more negative with a slow time-course, consistent with the slow development of sensitisation, reaching a value of −36 mV after 120 s exposure to carvacrol. The shift is rapidly and completely reversed on removal of agonist, but sensitisation can be seen to be conserved even if agonist is removed for times exceeding 240 s (Figure 5 C, D), a property that is shared by the negative shift of $V_{1/2}$, because both current and the shift in $V_{1/2}$ are seen to be enhanced following a second application of agonist (Figure 6 E).

In contrast to other voltage-dependent TRP channels, TRPA1 is inactivated by strong depolarisation (see Figure 6). A similar inactivation has been reported by some studies (Karashima et al., 2007, 2008; Macpherson et al., 2007; Andersson et al., 2008; Fajardo et al., 2008; Talavera et al., 2009) but not by others (Doerner et al., 2007b; Meseguer et al., 2008; Banke et al., 2010; Wan et al., 2013). It has been proposed that this discrepancy is due to differing factors in recording conditions that negatively shift the $V_{1/2}$ for inactivation to varying degrees (Wan et al., 2013). Our results clearly identify inactivation of TRPA1, both in steady-state I-V relations (Figure 6 C, D) and in tail currents (Figure 6 E), and show that channel inactivation is enhanced by prolonged
agonist exposure (Figure 6 C, D). In the absence of a clear explanation for TRPA1 inactivation at strongly positive voltages we restricted analysis of activation curves to membrane voltages below +100 mV, where inactivation is minimal.

A model for sensitisation of TRPA1

How is agonist-induced sensitisation caused? One possible explanation could be relief of voltage-dependent pore block by calcium, as has been reported for TRPV3 (Chung et al., 2005; Xiao et al., 2008b), although a more recent study has shown that a component of sensitisation of TRPV3 is calcium-independent and therefore resembles the sensitisation studied in the present paper (Liu et al., 2011). Another possibility is a time-dependent increase in pore diameter, which is enhanced under calcium-free conditions (Chen et al., 2009; Banke et al., 2010; Karashima et al., 2010; Bobkov et al., 2011). However, pore dilation occurs within less than 15 s of AITC application and well before maximal channel activation (Chen et al., 2009; Banke et al., 2010), which challenges the contribution of pore dilation for the long-lasting agonist-induced sensitisation that was shown here. A further possibility is that agonists may induce a transformation of the channel conformation leading to enhanced sensitivity to membrane voltage and therefore to sensitisation. We propose a model for TRPA1 sensitisation (Figure 7 A) in which the channel is not only reversibly gated by agonists but also, with a time constant of more than one minute, enters a sensitised conformational state ‘1’ that allows enhanced gating. This conformational change is likely to involve a slow shift in charge distribution within the TRPA1 molecule such that the gating charge responsible for voltage-dependent channel activation is activated at progressively more negative membrane potentials (Figure 6 E). Finally, with prolonged agonist application, more and more channels accumulate in this sensitised state ‘1’, explaining the observed slow shift in voltage dependence and the accompanying change in slope factor as well as the increased inward current (Figure 7 D).
Modelling of repetitive agonist application using experimentally determined parameters resembles our experimental observations. Even if the underlying biology is more complex, a simple model with four states and three transition time constants is sufficient to produce the major features of the slow current increase in response to agonist (Figure 7 B–D) and the shift in $V_{1/2}$ (Figure 7 D).

Alternative models which could generate a slow current increase have been considered, e.g. as described for TRPV3 where this was termed ‘hysteresis’ (Liu et al., 2011). Adopting that model, two sequential closed states before transition to one open state could generate hysteresis in case of a longer time constant between the two closed states compared to the transition to the open state. In such a scenario only the slowly rising amount of channels which can open would explain the hysteresis, and the observed $V_{1/2}$ shift would not be reflected. Alternatively, one closed and two sequential open states could also generate hysteresis, but a different kinetic upon agonist removal should be expected in this case. Finally, if in our model the transition $C_1\rightarrow O_1$ was at least an order of magnitude faster than $C_0\rightarrow O_0$, hysteresis could also occur, but this was excluded by our observations that activation and deactivation time constants are similar in the basal and sensitised states (see Results section).

Finally, we note that while activation of TRP channels by agonists or by voltage were initially thought to be equivalent (Voets et al., 2004), a more recent study has demonstrated that these two modes of activation in fact not equivalent (Matta & Ahern, 2007). In the case of TRPV1 and TRPM8, membrane voltage acts only as a partial agonist, in that the increase in channel open probability caused by voltage is much smaller than the increase in open probability caused by thermal activation, and at high agonist concentrations gating is voltage-independent.

**Physiological relevance of sensitisation of TRPA1**
Considering the physiological relevance of agonist-induced sensitisation of TRPA1, it is likely that it would initially be masked by calcium-mediated inhibition of the channel. However, the sensitising effect of agonists increases over time and sensitisation may eventually overcome the inhibition of the channel by calcium, leading in total to a sensitised channel state. Agonist-induced sensitisation could provide a mechanism for the detection of repeated or long-term exposure to harmful irritants. Such a mechanism would be especially appealing in the airways, as many TRPA1 agonists can be ingested or inhaled and the channel is implicated in the development of inflammatory airway diseases (Andrè et al., 2008; Birrell et al., 2009). This hypothesis is supported by recent findings of Kunkler et al. (2015) showing that long-term inhalation exposure of rats to sub-activating doses of the TRPA1 agonist acrolein led to increased meningeal blood flow in response to acute nasal challenge with mustard oil. Animals had been pre-exposed to acrolein four hours per day for four days, which agrees with our findings that agonist-induced sensitisation of TRPA1 is very long-lasting and potentially irreversible. This mechanism of TRPA1 sensitisation may therefore represent an important physiological function.

In summary, we have shown that prolonged agonist application sensitises the TRPA1 channel both in nociceptive neurons and when heterologously expressed and that this slow process is agonist-driven and is intrinsic to the channel itself. Sensitisation is accompanied by a slowly developing shift of voltage-dependent activation towards more negative membrane potentials and thus represents a slow gain-of-function. Agonist-induced sensitisation of TRPA1 may provide a mechanism for the detection of long-term exposure to harmful stimuli, which would be especially valuable in the airways, where many irritants activate TRPA1.
References


Additional Information

Competing interests

The authors declare no competing financial interests.

Author contributions

JEM, MJMF and PAM conceptualised and designed the experiments; JEM and MJMF collected and assembled the data; JEM, MJMF and PAM analysed and interpreted the data; JEM drafted the manuscript; MJMF and PAM revised the manuscript. All authors approved the final version of the manuscript. All persons designated as authors qualify for authorship and all those who qualify for authorship are listed.

Funding

Funded by grants from the Biotechnology and Biological Sciences Research Council, UK (BBSRC) to PAM, PhD studentship support from the Department of Pharmacology Cambridge, the Ernst Schering Foundation, the Deutsche Schmerzgesellschaft e.V. and the German Academic Exchange Service to JEM and a fellowship from the Alexander von Humboldt Foundation to MJMF.
Figure 1 Repeated activation of TRPA1 by agonists, but not by voltage, sensitises the channel in the absence of extracellular calcium. (A) Representative whole-cell voltage-clamp recording of a DRG neuron (holding potential −60 mV) showing that repeated application of AITC (50 µM; 40 s; 90 s gap) induces increasing inward currents in 0 [Ca\(^{2+}\)]o. (B) Repeated application of carvacrol (100 µM; 30 s; 60 s gap) to a DRG neuron also has a sensitising effect. The TRPA1-specific agonist AITC (50 µM; 40 s) was applied once at the end of the protocol. (C) Quantification of all experiments as in (A) and (B). Graph (left) shows peak current of each response, measured as current increase on application of agonist, and normalised to first response. Bar chart (right) shows fractional sensitisation measured at sixth response. AITC induced an 8.3 ± 2.5 fold sensitisation (\(p < 0.001\) compared to first response; \(n = 9\)); carvacrol induced a 1.9 ± 0.3 fold sensitisation (\(p = 0.01\) compared to first response; \(n = 9\)). * compared to first response. # compared to first response. (D–F) Similar recordings with HEK293t cells expressing hTRPA1 (holding potential −60 mV). Repeated application of AITC (50 µM; 15 s; 120 s gap) induced a 6.3 ± 1.5 fold sensitisation (\(p < 0.001\) compared to first response; \(n = 8\)) at the sixth response; carvacrol (100 µM; 15 s; 30 s gap) induced a 2.1 ± 0.2 fold sensitisation (\(p < 0.001\) compared to first response; \(n = 22\)). (G) Activation of TRPA1 by strong depolarisation has no sensitising effect. 15 voltage steps from −60 mV to +160 mV, duration 1 s, applied every 7 s. Same protocol repeated after a period of 5 min. Mean current 1624 ± 98 pA (67 ± 4 pA/pF, \(n = 10\)) (H) Same protocol applied to untransfected HEK293t cells elicited much smaller background current. Scale bars as in (G). Mean current 616 ± 41 pA (32 ± 3 pA/pF; \(p < 0.001\); \(n = 10\)) (I) Peak currents, normalised to the first response of the first protocol, do not increase with repeated activation of TRPA1 (circles), and there is no significant increase during the second protocol (squares) (all \(p \geq 0.34\); \(n = 8–10\)). (J) Voltage protocol similar to that used for agonist application. Voltage steps from −60 mV to
+100 mV, duration 15 s (bottom trace) applied with 30 s intervals between steps. Time point for measurement of steady-state (I_{ss}) currents is indicated by arrow. Scale bars 50 pA and 10 s. (K) Steady-state currents (I_{ss}), normalised to the first response. No significant increase in current amplitude (all p ≥ 0.68; n = 6–8).

Figure 2 Agonist-induced sensitisation does not rely on cysteine modification, ATP-signalling, phosphorylation or the formation of lipid rafts. Whole-cell voltage-clamp experiments in HEK293t cells transiently transfected with hTRPA1. (A) Mutating the three intracellular cysteine residues modified by electrophilic agonists (C621, C641 and C665) to serine (3C mutant) does not reduce the sensitisation induced by repeated application of carvacrol (200 µM; 15 s). (B) Complete removal of ATP potentiated sensitisation induced by carvacrol (100 µM; 15 s). Recordings were performed using ATP- and GTP-free intracellular solution and glucose-free extracellular solution. (C) Inhibiting intracellular protein kinase A (PKA) does not reduce the effect of carvacrol (100 µM; 15 s). The PKA inhibitor H89 (10 µM) was applied extracellularly throughout the recording. (D) Disruption of lipid rafts by methyl-β-cyclodextrin (MβCD, 5 mM for 15 min before recording) does not inhibit sensitisation induced by carvacrol. (E) An initial sustained carvacrol application (100 µM; 150 s) before switching to repetitive application stabilises the following repetitive responses. (F) Summary graph of fractional sensitisation measured at sixth response in all experiments as in (A–F). The control group is the same as in Figure 1 (E, F). In the 3C mutant, currents had increased 2.7 ± 0.4 fold (p < 0.001 compared to first response; n = 14). In ATP-free recordings, the increase was 4.0 ± 0.7 fold (p < 0.001 compared to first response; n = 4). In the presence of H89, current increase was 2.4 ± 0.2 fold (p < 0.001 compared to first response; n = 8). In the presence of MβCD, currents had increased 2.2 ± 0.3 fold (p < 0.001 compared to first response; n = 8). With the initial sustained carvacrol
application, currents had not increased at sixth response (1.0 ± 0.1 fold; n = 14). # compared to first response. * compared to control.

Figure 3 Sensitisation of TRPA1 by carvacrol is not caused by increased trafficking to the membrane. (A) Images show HEK293t cells transiently transfected with WT hTRPA1-V5. Scale bar 5 μm is the same for both images. Membrane staining by WGA (bottom) was used to create a juxtamembrane ROI that was superimposed on the image of TRPA1 fluorescence (top) to measure TRPA1 levels at the membrane. A separate ROI obtained from the fluorescence within the cell defined the cytoplasm excluding the nucleus. (B) Cells were either untreated (control; top row) or stimulated with carvacrol (100 μM; 5 min; bottom row) before fixation. Scale bar (5 μm) is the same for all images. (C) Ratio of TRPA1 expression at the membrane compared to the cytoplasm was not different between control cells and those stimulated with carvacrol (p = 0.336; n = 7–8). (D, E) TRPA1-expressing HEK293t cells were incubated with Brefeldin A (BFA, 5 μg/ml) for 2–3 hours (example trace) or 5–7 hours to abolish protein trafficking to the membrane prior to start of voltage-clamp experiments. Repetitive stimulation with carvacrol (100 μM; 15 s; 30 s gap) still induces pronounced sensitisation of inward currents. After 2–3 hours BFA, sensitisation at sixth response was 2.6 ± 0.4 fold (p = 0.08) and seventh response was increased significantly (2.9 ± 0.4; p = 0.015; both n = 7). After 5–7 hours, sensitisation at sixth response was already significant (2.5 ± 0.6 fold; p = 0.005; n = 6) (F, G) Repeated application of a saturating dose of carvacrol (5 mM; 6 s; 84 s gap) induces maximal currents that display tachyphylaxis. Third response is significantly smaller than the first (p = 0.034; n = 8). n.s. not significant. # compared to first response. * compared to 6th response in 100 μM carvacrol.
Figure 4 Different agonists cross-sensitise. (A) Representative voltage-clamp recordings in hTRPA1-expressing HEK293t cells, showing cross-sensitisation between AITC and carvacrol. Top: sensitisation of inward currents induced by carvacrol (100 µM; 15 s; 30 s gap). Bottom: recording in identical conditions but TRPA1 activated with AITC (50 µM; 150 s) before application of carvacrol. (B) Cross-sensitisation of response to carvacrol by AITC. First carvacrol-induced response is significantly larger following exposure to AITC ($p = 0.016; n = 8$ for AITC group, $n = 24$ for control). (C) Mutation S873V/T874L abolishes responses to carvacrol but not AITC. Representative recording (see Figure 1 for protocol) in HEK293t cells expressing the hTRPA1-S873V/T874L mutant. No response to carvacrol was observed. AITC 100 µM was applied at the end of the protocol and response was of normal amplitude. (D) Quantification of (C), plotting the average inward current for each agonist application ($n = 9$). (E) Ratiometric calcium imaging confirms deletion of carvacrol response in hTRPA1-S873V/T874L mutant. Experiments performed on HEK293t cells expressing either WT hTRPA1 (black) or hTRPA1-S873V/T874L mutant (grey). Ratio of fura-2 fluorescence excited at 340 nm and 380 nm plotted on vertical axis. Cells were exposed to carvacrol (12.5 µM) and AITC (50 µM) for 30 s each, followed by a 20 s application of ionomycin (5 µM) to induce a maximum response for comparison. Traces are averages of 30 (WT) and 167 (mutant) cells, SEM is represented by vertical lines. (F) Carvacrol does not cause sensitisation of responses to AITC in the S873V/T874L mutant. Responses of hTRPA1-S873V/T874L mutant (white bar; $n = 3$) to 50 µM AITC following 12 applications of 100 µM carvacrol were of similar magnitude to naïve responses to 50 µM AITC in WT channels (black bar; $n = 9; p = 0.99$). In contrast, WT channels that had been sensitised by repeated application of AITC (grey bar; $n = 8$) displayed significantly larger responses ($p = 0.015$ compared to white, $p < 0.001$ compared to black; one-way ANOVA with Bonferroni post hoc analysis). Values for the
unsensitised and sensitised WT channels are the same as in Figure 1 D & F, 1\textsuperscript{st} and 8\textsuperscript{th} response, respectively. # compared to S873V/T874L. * compared to WT unsensitised.

**Figure 5** Agonist-induced sensitisation of TRPA1 is independent of ion flux through the channel and is long-lasting. (A) Sensitisation of TRPA1 in HEK293t cells increases with agonist exposure even when the channel is blocked. Responses 5–8 to carvacrol (100 µM; 15 s) were blocked by the specific TRPA1 antagonist HC030031 (50 µM; 155 s) (see inset) and the measured inward currents (filled squares) are compared to control recordings without antagonist (open triangles). Responses 9–12 were comparable in amplitude to recordings where no antagonist had been applied ($p \geq 0.458$; $n = 7$ for HC030031-treated, $n = 21$ for control). (B) TRPA1 is significantly sensitised by agonist exposure during channel block ($p < 0.001$; $n = 7$). (C) TRPA1 sensitisation in HEK293t cells is long-lasting. Gap periods of 30 s, 120 s or 240 s (dotted lines) were left between applications of carvacrol (100 µM; 120 s; solid line). Sensitisation does not recover even with 240 s rest period. Sequence of gaps was changed at random between each cell. Arrows indicate time points for calculating the recovery ratio displayed in (D). Inset: prolonged stimulation with carvacrol (100 µM; 150 s) induces two phases of current increase (average ± SEM trace; $n = 16$). (D) The recovery ratio was calculated by measuring the early current at the end of the first steep increase ($I_{\text{early}}$) of each response and comparing it to the peak current ($I_{\text{peak}}$) of the previous response. None of the calculated recovery ratios were significantly different from 1 ($p \geq 0.24$; $n = 7–8$).

**Figure 6** Effect of repeated carvacrol application on the voltage dependence of TRPA1. (A) Representative time course of whole-cell currents elicited by two consecutive 120 s applications of 100 µM carvacrol, measured in hTRPA1-expressing
HEK293t cells at −80 mV (bottom trace) and +80 mV (top trace). Dotted line represents zero current level. At the coloured time points labelled 1–8, voltage dependence was tested using the step-pulse protocol illustrated in (B). (B) Currents recorded at the designated time points in (A) using the indicated step-pulse protocol of 80 ms voltage steps from a holding potential of −60 mV ranging from −140 mV to +220 mV in 30 mV increments, followed by a final step to +60 mV. Time points for the measurement of steady-state (I_{ss}) and tail (I_t) currents are indicated by arrows. (C) I-V relationships obtained at the end (I_{ss}) of the voltage steps illustrated in (B). Shown are average I-V curves for time points 1–4 during the first carvacrol application. (D) I-V relationships for time points 5–8 during the second carvacrol application. (E) Normalised tail currents measured at +60 mV at the indicated time points. Curve fitting was restricted to the voltage domain below +100 mV in order to avoid channel inactivation at strongly depolarised membrane potentials (see main text). Data points that were not included in the fit are shown as open symbols. Solid lines are best fits to Boltzmann functions (n = 11 cells). The following V_{1/2} values and slope factors (in brackets) were obtained for the given time points: time point 1, +170 mV (54 mV); time point 2, +94 mV (75 mV); time point 4, −36 mV (114 mV); time point 5, +179 mV (57 mV), time point 6, +22 mV (95 mV); time point 8, −132 mV (84 mV).

**Figure 7 Model of agonist-induced sensitisation of TRPA1.** (A) Hypothetical model containing two open (O_0, O_1) and two closed (C_0, C_1) channel states. The gating of TRPA1 by agonist and voltage is displayed in the horizontal direction and is controlled by the opening and closing time constants τ_1 and τ_2 which depend on both membrane voltage and agonist concentration. The slow agonist-induced sensitisation (vertical direction, τ_3) is independent of channel gating and drives the transition from C_0/O_0 to the sensitised state C_1/O_1, leading to a slow and progressive accumulation of channels.
in the sensitised state (C\textsubscript{1}/O\textsubscript{1}). This accumulation means that the fraction of open
channels at resting membrane potential is very different in the unsensitised and the
sensitised states and this underlies the shift in the voltage dependence of channel
activation shown in Figure 6 E. Experimentally, the agonist-dependent channel
activation and deactivation rate was similar in both the unsensitised and the sensitised
states (see main text), so the same values of \( \tau_1 \) and \( \tau_2 \) were used to describe agonist-
dependent activation and deactivation in the unsensitised and the sensitised states and
at the resting membrane voltage. Agonist-induced sensitisation is long-lasting and no
reversal was observed (dotted arrows). Upon washout of agonist channels rapidly
close by reverting from O\textsubscript{0} to C\textsubscript{0} and from O\textsubscript{1} to C\textsubscript{1}. The thickness of arrows reflects the
transition rates of the respective process at physiological membrane potentials in the
absence of agonist. (B) Based on the model shown in (A), the expected inward
currents upon repetitive carvacrol stimulation were simulated. In the model an
increasing current (black line, left axis) is generated by the agonist-dependent
transition from state 0 into the sensitised state 1. The fraction of channels in the
sensitised state 1 is shown by the red line (right axis). The overall increase in current in
the model matches the experimental observation (see for example Figure 1 E). Note
that in voltage-clamp recordings, the current reaches a plateau or briefly decreases
within 15 s (see Figure 5 C inset), reflecting a desensitising component which is
omitted in the model for simplicity. (C) Average \( V_{1/2} \) values of channel opening
measured as shown in Figure 6 E were fitted by a double-exponential function (red
line) to derive a time constant \( \tau_3 \) for the slow agonist-induced sensitisation. The value of
\( \tau_1 = 3.1 \) s, the measured time constant of current activation following agonist
application (see Results section), provided a reasonable fit to the rapid phase of
negative shift of \( V_{1/2} \). The slow \( V_{1/2} \) shift had a time constant of \( \tau_3 = 130 \pm 27 \) s (\( n = 11 \)
cells). (D) We simulated the voltage-dependent open probability of TRPA1 according to
the four-state model in (A). Following carvacrol application, the voltage-dependent
open probability shows a transition from \( C_0 \) to \( O_0 \) with a time constant of 3.1 s (see
above and Results section). As a result the current at \(-60 \text{ mV}\) increases from 0.014 to
0.053 of the maximal current. Additional lines reflect the slow transition from \( O_0 \) to \( O_1 \).
This transition, with a time constant of 130 s (see C), increases the current at \(-60 \text{ mV}\)
from 0.053 to 0.892 of the maximum. Note that the mixture of two states \( O_0 \) and \( O_1 \)
means that the slope of the curve is decreased during the transition period, as was
seen in Figure 6 E.